




RealRate

PHARMACEUTICAL 2013

Sonnet Biotherapeutics Holdings Inc
Rank 75 of 218



RealRate

The First AI Rating Agency

www.realrate.ai



PHARMACEUTICAL 2013

Sonnet Biotherapeutics Holdings Inc Rank 75 of 218



The relative strengths and weaknesses of Sonnet Biotherapeutics Holdings Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sonnet Biotherapeutics Holdings Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 94% points. The greatest weakness of Sonnet Biotherapeutics Holdings Inc is the variable Other Expenses, reducing the Economic Capital Ratio by 72% points.

The company's Economic Capital Ratio, given in the ranking table, is 287%, being 67% points above the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	2,030
Cost of Goods Sold	0
Intangible Assets	956
Liabilities, Current	1,773
Liabilities, Non-Current	186
Other Assets	2,344
Other Compr. Net Income	-4.4
Other Expenses	7,154
Other Liabilities	159
Other Net Income	-505
Other Revenues	6,883
Property and Equipment	2,316
Research and Development	0
Selling, General and Administrative Expense	2,618

Output Variable	Value in 1000 USD
Assets	7,646
Liabilities	2,118
Expenses	9,772
Revenues	6,883
Stockholders Equity	5,529
Net Income	-3,395
Comprehensive Net Income	-3,397
BaseVar	13,465
ECR before LimitedLiability	177%
Economic Capital Ratio	287%